Eli Lilly tested tirzepatide (the active ingredient in Zepbound) combined with eloralintide, an experimental drug targeting the amylin hormone rather than GLP-1. After 48 weeks, the combination produced weight loss of up to 23.3%, versus 14.8% with tirzepatide alone and 12.3% with eloralintide alone. However, discontinuation rates due to side effects reached as high as 27%, though Lilly’s Ken Custer noted that high discontinuation was also seen with tirzepatide in a mid-stage trial and that dosing can matter. The author views the results as a net positive but flags a steep valuation, with a market cap above $1 trillion and the stock trading near 40 times trailing earnings after rising around 10% this year.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Related news
- How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story
Eli Lilly's exploratory Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound in adults with moderate-to-severe plaque psoriasis and obesity or overweight changed far more immune and metabolic biomarkers than Taltz alone, with broader responses emerging as early as Week 12. The findings point to a possible immunometabolic link between psoriasis and obesity, which could let Lilly pair its immunology and obesity portfolios. The article says the data does not materially change the near-term focus on obesity and diabetes volumes or the risks from GLP-1 pricing pressure and litigation. It also cites Phase 2b EloraTZP results combining eloralintide with tirzepatide. The article's investment narrative projects $118.9 billion in revenue and $50.1 billion in earnings by 2029, implying a fair value of $1,329, about 12% above the current price.
- Will Eli Lilly Do a Stock Split Before the End of 2026?
The article argues Eli Lilly is unlikely to announce a stock split before the end of 2026, even though its share price is near $1,200 and its valuation exceeds $1 trillion. The company last split its stock in 1997 on a 2-for-1 basis, after earlier splits in 1995, 1989 and 1986. The author notes that splits are at management's discretion, and CEO David A. Ricks, who has led the company since 2017, has not announced one. Despite this, the article considers Eli Lilly a solid long-term holding, citing its dominance in the anti-obesity drug market and its recent dividend increases.
- Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.
Eli Lilly (LLY) shares have pulled back about 8% in recent weeks, after rising 41% over the past 12 months. The article attributes the decline mainly to investors taking profits after a 50% gain in less than four months that pushed the stock to an all-time high in August. U.S. prices for its products fell 3% year over year due to Zepbound and Mounjaro, or 9% excluding rebates and discounts, and the stock trades at 38.6 times trailing earnings versus 23.6 for the S&P 500. The author argues that overwhelming demand for these drugs will keep sales rising, and that over the past 10 years the stock fell by at least 8% more than 20 times yet still returned more than 14x. Of 23 analysts rating the stock over the last three months, 20 recommend buy or better, with a consensus target implying around 16% upside.
- Micron Just Raised Its Buyback Authorization to $35 Billion. Prediction: It Spends More Buying Back Stock in the Next Year Than in the Past 8 Combined.
Micron's board raised its buyback authorization to $35.16 billion on Oct. 8, as disclosed in its annual report filed Oct. 9. Almost all of that figure comes from one quarter: the $2.16 billion left under the earlier program plus 100% of the last quarter's adjusted free cash flow after dividends, about $33 billion. The author expects Micron to spend more on buybacks in the next year than the $7.84 billion it spent over the past eight fiscal years, though the authorization does not force purchases and CHIPS Act grant conditions restrict repurchases early on. At a share price near $985, the full authorization would buy only about 35 million shares, roughly 3% of the 1.13 billion outstanding, so the effect on share count and earnings per share may be small. The author still sees the stock as reasonable at about 13 times fiscal 2026 earnings, but says memory prices are likely to drive its next move more than buybacks do.
Related markets
Latest news
- Intel stock pops after JPMorgan gives a Neutral upgrade
JPMorgan (JPM) upgraded Intel (INTC) to Neutral from Underweight. The note points to improving execution under CEO Lip-Bu Tan, potential foundry customers for next-generation manufacturing, and rising earnings estimates for 2027 and 2028.
- Intel leads chip stocks higher as investors jump back into AI trade
Chip stocks rebounded on Monday as investors bought the dip after last week's steep AI trade sell-off. The PHLX Semiconductor Index (^SOX) rose 2%, reversing a recent semiconductor rout. Intel (INTC) jumped 5% after JPMorgan upgraded the stock to Buy, citing "solid execution." Nvidia (NVDA) and AMD (AMD) also gained, while a Goldman Sachs upgrade of CoreWeave (CRWV) to Buy from Neutral helped lift AI sentiment. Arm Holdings (ARM), Micron Technology (MU) and SK Hynix (SKHY) also rebounded after sharp declines last week.
- Netflix stock is down roughly 25% in 2026 as Q3 earnings loom
Netflix (NFLX) reports third-quarter results after the bell on Tuesday, with the stock down more than 25% this year and closing Friday near $70, versus $93.76 at the end of 2025. Investors are worried about slowing viewership, competition from YouTube, and live sports moving to Amazon Prime Video and HBO Max. Last week Netflix cut about 6% of its workforce (roughly 1,000 employees) and named Peter Rice its new chief content officer, and five firms lowered price targets in October. Analysts expect EPS of $0.82 on revenue of $12.88 billion, up about 12% from a year earlier, in line with Netflix's own forecast. KeyBanc's Justin Patterson wants more content investment, product changes, expense cuts and a possible first-ever dividend.
- Cleveland-Cliffs Jumps 10% on Strongest Quarter in Three Years; Nucor and Steel Dynamics Edge Higher
Cleveland-Cliffs (CLF) rose 10% to $13.29 after reporting third-quarter adjusted EBITDA of $612 million, beating its $575 million guidance and up sharply from $143 million a year earlier. Revenue of $5.61 billion missed the $5.72 billion expected, though sales rose 18.6% year over year on a higher average net selling price of $1,177 per ton and larger shipments. Management said imports remain well below historical levels, but it indefinitely idled the galvanizing lines at its Canadian unit Stelco due to oversupply. The company guided to about $715 million of adjusted EBITDA in Q4 and said 2027 adjusted EBITDA should exceed $4 billion based on current index price forecasts. Its target is to bring net debt to EBITDA below 2.5x by mid-2027.
- Tech rebounds as semiconductor stocks jump: AlphaCheck
Stocks were mostly higher on Monday as investors turned their focus to earnings season, with semiconductor stocks rebounding after last week's sharp sell-off. The Tech sector (XLK) rose, led by Nvidia (NVDA), AMD (AMD), Micron (MU) and SK Hynix (SKHY). Intel (INTC) also jumped after JPMorgan analysts upgraded the stock, while CoreWeave (CRWV), hammered last week, rebounded on a Goldman Sachs upgrade. Investors are watching this week's reports from Netflix (NFLX), SpaceX (SPCX), Tesla (TSLA) and Meta (META). The 10-year Treasury (^TNX) yield hovered near 5.1%, while Brent crude (BZ=F) dropped to $108 per barrel and WTI (CL=F) hovered below $98.
- AI capex may be Meta's biggest earnings test
Meta Platforms (META) reports third-quarter earnings after the close on Wednesday, alongside a wave of Big Tech peers. The GAAP EPS estimate is $3.54, though that figure may be messy because a legal settlement will be included and analysts differ on how it will be accounted for. Options imply a 3.2% move in either direction, the smallest since the fourth-quarter report before last. Estimates for next year's capex vary widely: Wedbush near $250 billion, Evercore ISI $210 billion, Bank of America $205 billion and Dan Ives around $194 billion. Most analysts say that spending is acceptable if Meta provides a Muse roadmap and confidence it can monetize it, and the stock is up about seven and a half percent year to date.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.